U.S. Markets closed

Baron Growth Instl (BGRIX)

Nasdaq - Nasdaq Delayed Price. Currency in USD
Add to watchlist
71.86+0.44 (+0.62%)
At close: 5:10PM EDT
People also watch
Full screen
Previous Close71.42
YTD Return16.52%
Expense Ratio (net)1.05%
Morningstar Rating★★★★
Morningstar Risk Rating★★★
Last Cap Gain0.00
Net Assets6.13B
Beta (3y)0.96
Holdings Turnover4.68%
Last Dividend0.00
Inception DateMay 29, 2009
Average for CategoryN/A
  • Reuters2 years ago

    Baron Growth fund adds biotechs Atara, ConforMIS to portfolio

    The $7 billion Baron Growth fund initiated positions in biotechnology firms Atara Biotherapeutics Inc and ConforMIS Inc during a sell-off in biotech companies last quarter, according to a letter to shareholders. Atara looks attractive because of its T-cell therapy that targets cancer-specific antigens, fund manager Ron Baron wrote. ConforMIS, meanwhile, uses 3D printing technology to develop custom implants for joint replacement procedures and is well-positioned to take market share, he wrote.

  • We're sorry this is all we were able to find about this topic.